alzheimers disease - Page 1 | CARLAT PUBLISHING

Research Update

Which Leisure Activities Can Lower Dementia Risk?

January 1, 2025

Paroma Mitra, MD. Dr. Mitra has served as a consultant for Bristol Meyers Squibb. Relevant financial relationships listed for the author have been mitigated.

Can the way you spend your free time protect your brain? New findings suggest leisure activities may reduce the risk of developing dementia.

Research Update

Linking Alzheimer’s and Depression in Patients after Fifty

January 1, 2025

Talya Shahal, MD.

Talya Shahal, MD. Dr. Shahal has no financial relationships with companies related to this material.

Depression could be an early sign of Alzheimer’s— it’s always a good idea to monitor cognition in older adults with depression.

News of Note

News of Note: Donanemab Gains FDA Approval for Early Alzheimer’s Treatment

October 1, 2024

Stephanie Collier, MD and Talia Puzantian, PharmD, BCPP

Stephanie Collier, MD and Talia Puzantian, PharmD. Dr. Collier and Dr. Puzantian have no financial relationships with companies related to this material.

The FDA recently approved donanemab for early Alzheimer’s, offering new hope by slowing cognitive decline.

Expert Q&A

Disparities in Dementia Diagnosis

October 1, 2024

Nicolás Pérez Palmer, MD

Nicolás Pérez Palmer, MD

Assistant Professor of Psychiatry, Yale School of Medicine, New Haven, CT; Director of Clinical Research Services, Latino Community, Alzheimer’s Disease Research Unit; Integrated Firm Director, Psychiatry, VA Connecticut Healthcare System.

Dr. Pérez Palmer has no financial relationships with companies related to this material.

Dr. Pérez Palmer explores health disparities in geriatric psychiatry, focusing on how social determinants affect dementia diagnosis and treatment among underrepresented populations, while addressing strategies to improve equitable care for older adults.

News of Note

Advances in Alzheimer’s Diagnosis: AIRAmed and Labcorp

January 1, 2024

Stephanie Collier, MD

Stephanie Collier, MD. Dr. Collier has no financial relationships with companies related to this material.

Two new advances may help us detect Alzheimer’s disease and other dementias.

News of Note

Brexpiprazole

October 31, 2023

Stephanie Collier, MD and Talia Puzantian, PharmD, BCPP

Stephanie Collier, MD, MPH, and Talia Puzantian, PharmD. Dr. Collier and Dr. Puzantian have no financial relationships with companies related to this material.

Consider other treatments before reaching for brexpiprazole, even though it’s FDA-approved to treat agitation in dementia due to Alzheimer’s disease.

Clinical Update

Safe Driving for Older Adults

October 31, 2023

Francisco Covino-Deaso, MSN, CNP, PMHNP-BC and Jennifer Holiman, MSN, CNP, PMHNP-BC

Francisco Covino-Deaso, MSN, CNP, PMHNP-BC. Psychiatric nurse practitioner, Partial Program (PHP) at HRI Hospital, Brookline, MA.

Jennifer Holiman, MSN, CNP, PMHNP-BC. Psychiatric nurse practitioner, geriatric psychiatry outpatient program and geriatric psychiatry research program, McLean Hospital, Belmont, MA.

Mr. Covino-Deaso and Ms. Holiman have no financial relationships with companies related to this material.

Understanding when patients are no longer safe to drive is no easy task. We’ll show you how to estimate driving abilities from your clinic, and what to do when you’re concerned.

Research Update

Can Physical Activity Offset Cognitive Decline?

July 11, 2023

Susan L. Siegfreid, MD

Susan L. Siegfreid, MD. Dr. Siegfreid has no financial relationships with companies related to this material.

Physical activity may slow cognitive decline, especially in older adults with biomarkers of neurodegeneration.

RESEARCH UPDATE

Less Sleep Correlated with Dementia

October 1, 2022

Talya Shahal, MD.

Talya Shahal, MD. Dr. Shahal, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

This study supports an association between short sleep duration in middle life and an increasedrisk of dementia.

RESEARCH UPDATE

Can Pimavanserin Treat Psychosis in Patients With Dementia?

October 1, 2022

James Black, MD

James Black, MD. Dr. Black, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

This study suggests that patients started on pimavanserin for dementia and psychosis should probably continue it to prevent relapse, but we will need more data for clarity given flaws in the study design.